×
About 24,653 results

ALLMedicine™ Metastatic Breast Cancer Center

Research & Reviews  6,174 results

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT04750928

Jun 24th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome (incidence of 1:3000), which results in the development of progressive tumor and non-tumor manifestations, the majority of which have no effective medical therap...

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05430399

Jun 24th, 2022 - It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
https://clinicaltrials.gov/ct2/show/NCT05413304

Jun 24th, 2022 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced ...
https://clinicaltrials.gov/ct2/show/NCT05306340

Jun 24th, 2022 - This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth f...

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
https://clinicaltrials.gov/ct2/show/NCT04895358

Jun 24th, 2022 - The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human...

see more →

Guidelines  10 results

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients w...
https://doi.org/10.1016/j.annonc.2021.09.019
Annals of Oncology : Official Journal of the European Soc... Gennari A, André F et. al.

Oct 23rd, 2021 - ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.|2021|Gennari A,André F,Barrios CH,Cortés J,de Azambuja E,|diagnosis,therapy,

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0016
Journal of the National Comprehensive Cancer Network : JN... Gradishar WJ, Anderson BO et. al.

Apr 8th, 2020 - Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor ...

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clini...
https://doi.org/10.1200/JOP.2017.027672
Journal of Oncology Practice; Van Poznak C, Somerfield MR et. al.

Oct 17th, 2017 - Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.|2017|Van Poznak C,Somerfield MR,Moy B,|therapeutic use,drug therapy,secondary,drug therapy,pa...

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Soci...
https://doi.org/10.1200/JCO.2016.67.1487
Journal of Clinical Oncology : Official Journal of the Am... Rugo HS, Rumble RB et. al.

May 25th, 2016 - To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 20...

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076042
Journal of Clinical Oncology : Official Journal of the Am... Partridge AH, Rumble RB et. al.

Sep 4th, 2014 - To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer. A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1...

see more →

Drugs  247 results see all →

Clinicaltrials.gov  1,909 results

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT04750928

Jun 24th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome (incidence of 1:3000), which results in the development of progressive tumor and non-tumor manifestations, the majority of which have no effective medical therap...

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05430399

Jun 24th, 2022 - It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
https://clinicaltrials.gov/ct2/show/NCT05413304

Jun 24th, 2022 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced ...
https://clinicaltrials.gov/ct2/show/NCT05306340

Jun 24th, 2022 - This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth f...

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
https://clinicaltrials.gov/ct2/show/NCT04895358

Jun 24th, 2022 - The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human...

see more →

News  1,519 results

Metastatic BC and brain metastases: Etirinotecan pegol fails to improve survival in phase 3
https://www.mdedge.com/hematology-oncology/article/255692/breast-cancer/metastatic-bc-and-brain-metastases-etirinotecan

Jun 23rd, 2022 - Key clinical point: Etirinotecan pegol failed to prolong survival compared with chemotherapy in patients with metastatic breast cancer (BC) and stable pretreated brain metastases (BM). Major finding: The median overall survival (hazard ratio [HR].

Elacestrant prolongs survival in previously treated ER+/HER2− advanced BC
https://www.mdedge.com/hematology-oncology/article/255689/breast-cancer/elacestrant-prolongs-survival-previously-treated-er

Jun 23rd, 2022 - Key clinical point: Elacestrant significantly improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine monotherapy in previously treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor re.

Survival for elderly breast cancer patients 25% after 4 years
https://www.mdedge.com/hematology-oncology/article/255558/asco-breast-cancer/survival-elderly-breast-cancer-patients-25
Walter Alexander

Jun 20th, 2022 - A study of elderly patients with HER2-positive/HR-negative metastatic breast cancer finds a significantly shorter median overall survival in actual clinical practice than younger counterparts. After 46 months of treatment, the survival rate was on.

Neighborhood analysis links breast cancer outcomes to socioeconomic status
https://www.mdedge.com/hematology-oncology/article/255556/asco-breast-cancer/neighborhood-analysis-links-breast-cancer
Jim Kling

Jun 20th, 2022 - A neighborhood analysis of socioeconomic status conducted in the Pittsburgh area found worse metastatic breast cancer survival outcomes among patients of low socioeconomic status. The findings suggest that race is not a relevant factor in outcomes.

Elacestrant Benefit in Breast Cancer, but Compared to What?
https://www.medscape.com/viewarticle/975720

Jun 16th, 2022 - Questions are now being asked about the comparator arm of a phase 3 trial in advanced breast cancer in which the investigational drug elacestrant (developed by Menarini/Radius Health) showed enough benefit for the companies to consider applying fo...

see more →

Patient Education  2 results see all →